The University of Southampton
University of Southampton Institutional Repository

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders
A synergistic effect of fludarabine (FLU) and cyclophosphamide (CY) has been extensively demonstrated in the treatment of chronic lymphoproliferative disorders (CLD), although a high incidence of severe neutropenia and infectious complications, particularly in elderly patients, have been reported. Based on a previous clinical experience in elderly CLD patients treated with a combination of low-dose intravenous (i.v.) FLU and CY in whom we obtained good response rates and negligible toxicity, we tested efficacy and safety of the new oral formulation of FLU combined with CY at low doses. A total of 28 elderly patients with relapsed/refractory or untreated CLD were treated with oral FLU and CY (25 and 150 mg/m2 respectively, both for 4 days every 4 weeks). The treatment design consisted in four consecutive courses and the median value of courses per patient was 3. Overall, 25 out of 28 evaluable patients were responsive to the treatment (six CR and 19 PR; ORR 89%), while the remaining three patients did not show any appreciable response (two progressive and one stable disease). Hematological toxicity was low in the majority of patients (grade 2-3 neutropenia/anemia in 8/28 cases); however, two fatal infections occurred and one additional patient died because of disease progression. Extra-hematological toxicity was generally mild. This preliminary report suggests that oral combination of FLU and CY at low dose is effective as the i.v. formulation and standard doses, since it may induce rapid responses in about 90% of elderly patients with CLD, with an acceptable toxicity.
1466-4860
472-474
Fabbri, Alberto
01268e1d-6b5a-44e0-9702-a25caa971f59
Lenoci, Mariapia
e7a3fdb7-9263-45b1-b627-9d85c349abca
Gozzetti, Alessandro
18591c75-cbee-444e-972e-b13dce8340e7
Marotta, Giuseppe
7cfa6aac-457c-4b9c-a279-5988a69706c9
Raspadori, Donatella
185f6866-6d10-4f86-9add-72938cea80b3
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Lauria, Francesco
f01f163b-abcb-4aad-b952-f4356692f519
Fabbri, Alberto
01268e1d-6b5a-44e0-9702-a25caa971f59
Lenoci, Mariapia
e7a3fdb7-9263-45b1-b627-9d85c349abca
Gozzetti, Alessandro
18591c75-cbee-444e-972e-b13dce8340e7
Marotta, Giuseppe
7cfa6aac-457c-4b9c-a279-5988a69706c9
Raspadori, Donatella
185f6866-6d10-4f86-9add-72938cea80b3
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Lauria, Francesco
f01f163b-abcb-4aad-b952-f4356692f519

Fabbri, Alberto, Lenoci, Mariapia, Gozzetti, Alessandro, Marotta, Giuseppe, Raspadori, Donatella, Forconi, Francesco and Lauria, Francesco (2004) Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. The Hematology Journal, 5 (6), 472-474. (PMID:15570287)

Record type: Article

Abstract

A synergistic effect of fludarabine (FLU) and cyclophosphamide (CY) has been extensively demonstrated in the treatment of chronic lymphoproliferative disorders (CLD), although a high incidence of severe neutropenia and infectious complications, particularly in elderly patients, have been reported. Based on a previous clinical experience in elderly CLD patients treated with a combination of low-dose intravenous (i.v.) FLU and CY in whom we obtained good response rates and negligible toxicity, we tested efficacy and safety of the new oral formulation of FLU combined with CY at low doses. A total of 28 elderly patients with relapsed/refractory or untreated CLD were treated with oral FLU and CY (25 and 150 mg/m2 respectively, both for 4 days every 4 weeks). The treatment design consisted in four consecutive courses and the median value of courses per patient was 3. Overall, 25 out of 28 evaluable patients were responsive to the treatment (six CR and 19 PR; ORR 89%), while the remaining three patients did not show any appreciable response (two progressive and one stable disease). Hematological toxicity was low in the majority of patients (grade 2-3 neutropenia/anemia in 8/28 cases); however, two fatal infections occurred and one additional patient died because of disease progression. Extra-hematological toxicity was generally mild. This preliminary report suggests that oral combination of FLU and CY at low dose is effective as the i.v. formulation and standard doses, since it may induce rapid responses in about 90% of elderly patients with CLD, with an acceptable toxicity.

This record has no associated files available for download.

More information

Published date: 2004
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 358180
URI: http://eprints.soton.ac.uk/id/eprint/358180
ISSN: 1466-4860
PURE UUID: 24bc2474-48cf-4155-8098-8a6d2f19d321
ORCID for Francesco Forconi: ORCID iD orcid.org/0000-0002-2211-1831

Catalogue record

Date deposited: 14 Nov 2013 14:01
Last modified: 24 Nov 2022 02:44

Export record

Contributors

Author: Alberto Fabbri
Author: Mariapia Lenoci
Author: Alessandro Gozzetti
Author: Giuseppe Marotta
Author: Donatella Raspadori
Author: Francesco Lauria

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×